|
Journal of Zhejiang University SCIENCE B
ISSN 1673-1581(Print), 1862-1783(Online), Monthly
2020 Vol.21 No.12 P.948-954
Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China
Abstract: The aim of this study was to evaluate the safety of an antiviral regimen of protease inhibitors combined with Arbidol (umifenovir) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia patients. The genomic sequence of SARS-CoV-2 is highly homologous to that of SARS-CoV (Zhou et al., 2020). Previously published basic and clinical research on anti-SARS-CoV treatment found that lopinavir/ritonavir (LPV/r) could improve the prognosis of SARS patients (Chan et al., 2003; Chu et al., 2004). Darunavir (DRV) is another protease inhibitor that blocks the binding of SARS-CoV-2 to human angiotensin-converting enzyme 2 (Omotuyi et al., 2020). The broad-spectrum antiviral drug Arbidol (umifenovir) also shows in vitro anti-SARS-CoV activity (Khamitov et al., 2008).
Key words: SARS-CoV; Lopinavir; Darunavir; Pneumonia; Lipid metabolism
关键词组:
References:
Open peer comments: Debate/Discuss/Question/Opinion
<1>
DOI:
10.1631/jzus.B2000204
CLC number:
R511
Download Full Text:
Downloaded:
1892
Download summary:
<Click Here>Downloaded:
1694Clicked:
2965
Cited:
0
On-line Access:
2020-12-09
Received:
2020-04-17
Revision Accepted:
2020-10-22
Crosschecked:
2020-11-11